149 related articles for article (PubMed ID: 27453980)
1. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
Owens DR
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic and pharmacokinetic evaluation of insulin glargine U300 for the treatment of type 1 diabetes.
Hurren KM; O'Neill JL
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1521-1526. PubMed ID: 27710135
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.
Porcellati F; Lucidi P; Candeloro P; Cioli P; Marinelli Andreoli A; Curti G; Bolli GB; Fanelli CG
Diabetes Care; 2019 Jan; 42(1):85-92. PubMed ID: 30305345
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
5. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes.
Shiramoto M; Eto T; Irie S; Fukuzaki A; Teichert L; Tillner J; Takahashi Y; Koyama M; Dahmen R; Heise T; Becker RH
Diabetes Obes Metab; 2015 Mar; 17(3):254-60. PubMed ID: 25425297
[TBL] [Abstract][Full Text] [Related]
6. Clinical Pharmacokinetics and Pharmacodynamics of Insulin Glargine 300 U/mL.
Clements JN; Threatt T; Ward E; Shealy KM
Clin Pharmacokinet; 2017 May; 56(5):449-458. PubMed ID: 27699623
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of insulin glargine U-300 versus insulin glargine U-100 on nocturnal hypoglycemia and glycemic control in type 1 and type 2 diabetes: a systematic review and meta-analysis.
Díez-Fernández A; Cavero-Redondo I; Moreno-Fernández J; Pozuelo-Carrascosa DP; Garrido-Miguel M; Martínez-Vizcaíno V
Acta Diabetol; 2019 Mar; 56(3):355-364. PubMed ID: 30506484
[TBL] [Abstract][Full Text] [Related]
8. Insulin glargine 300 units/mL: a guide for healthcare professionals involved in the management of diabetes.
Strong J; Kruger D; Novak L
Curr Med Res Opin; 2017 Apr; 33(4):785-793. PubMed ID: 28132529
[TBL] [Abstract][Full Text] [Related]
9. New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.
Becker RH; Dahmen R; Bergmann K; Lehmann A; Jax T; Heise T
Diabetes Care; 2015 Apr; 38(4):637-43. PubMed ID: 25150159
[TBL] [Abstract][Full Text] [Related]
10. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.
Steinstraesser A; Schmidt R; Bergmann K; Dahmen R; Becker RH
Diabetes Obes Metab; 2014 Sep; 16(9):873-6. PubMed ID: 24571126
[TBL] [Abstract][Full Text] [Related]
11. INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
Munshi MN; Gill J; Chao J; Nikonova EV; Patel M
Endocr Pract; 2018 Feb; 24(2):143-149. PubMed ID: 29106816
[TBL] [Abstract][Full Text] [Related]
12. Insulin Glargine 300 U/mL: A Review in Diabetes Mellitus.
Blair HA; Keating GM
Drugs; 2016 Mar; 76(3):363-74. PubMed ID: 26821280
[TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation.
Owens DR; S Bailey T; Fanelli CG; Yale JF; Bolli GB
Diabetes Metab; 2019 Sep; 45(4):330-340. PubMed ID: 30496834
[TBL] [Abstract][Full Text] [Related]
14. A review of the safety and efficacy data for insulin glargine 300 units/ml, a new formulation of insulin glargine.
Dailey G; Lavernia F
Diabetes Obes Metab; 2015 Dec; 17(12):1107-14. PubMed ID: 26139151
[TBL] [Abstract][Full Text] [Related]
15. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Goldman J; Kapitza C; Pettus J; Heise T
Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
[TBL] [Abstract][Full Text] [Related]
16. Insulin glargine 300 units/mL: A new basal insulin product for diabetes mellitus.
Clements JN; Bello L
Am J Health Syst Pharm; 2016 Mar; 73(6):359-66. PubMed ID: 26953280
[TBL] [Abstract][Full Text] [Related]
17. [New generation of insulins: glargine U300. Summary of clinical evidence].
Musso C; Capurro L; Mingote E; Forti L; Guaita MS
Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
[TBL] [Abstract][Full Text] [Related]
18. New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus.
Goldman J; White JR
Ann Pharmacother; 2015 Oct; 49(10):1153-61. PubMed ID: 26238470
[TBL] [Abstract][Full Text] [Related]
19. [INSULIN GLARGINE 300 U/mL (TOUJEO®)].
Scheen AJ
Rev Med Liege; 2016 Feb; 71(2):101-7. PubMed ID: 27141654
[TBL] [Abstract][Full Text] [Related]
20. Incorporating Long-Acting Insulin Glargine Into the UVA/Padova Type 1 Diabetes Simulator for In Silico Testing of MDI Therapies.
Visentin R; Schiavon M; Giegerich C; Klabunde T; Man CD; Cobelli C
IEEE Trans Biomed Eng; 2019 Oct; 66(10):2889-2896. PubMed ID: 30735983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]